← Russell 3000 cross-section

NKTR NEKTAR THERAPEUTICS

Trailing twelve months to 2026-06-30 · as filed 2026-08-14, not restated
Healthcare

Scale

Market cap
$2.5bn
Revenue TTM
$55m
Net income TTM
$-157m
Free cash flow
$-234m
Composite score
40.7
Sector rank
#1501

Valuation

P / E
EV / EBITDA
EV / sales
33.8
FCF yield
-9.25%
Earnings yield vs 10-yr
-10.94pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-287.8%
EBITDA margin
ROE
-17.4%
ROIC
-64.3%
Revenue growth
-27.1%

Insider activity, last 90 days

Net open-market
$-1.99m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We have financed our operations primarily through public and private placements of debt and equity securities, royalties and product sales, as well as, revenue from upfront and milestone payments under our strategic collaboration agreements. In connection with the April 2025 Shelf Registration Statement, in April and November 2025, we also entered equity distribution agreements with Piper Sandler & Co. and BTIG, LLC, relating to the sale of our common stock having an aggregate offering price of up to $ 75.0 million (the April 2025 ATM Sales Agreement) and $ 110.0 million ( the November 2025 ATM Sales Agreement), respectively . We agreed to pay Piper Sandler & Co. …NEKTAR THERAPEUTICS, 10-Q, period ended 2026-06-30, filed 2026-08-14

Read the full passage →